6 May 2020 09:36
Intelligent Ultrasound Group plc
("Intelligent Ultrasound" or the "Company")
Director Dealings
Intelligent Ultrasound (AIM: MED), the intelligent ultrasound software and simulation company, announces that further to the Company's announcements on 17 April 2020 and 4 May 2020, certain Directors have, following Admission today, acquired a total of 409,523 Ordinary Shares in the Company via the Placing, as detailed below:
Name | Title | Number of Existing Ordinary Shares# | Number of Placing Shares subscribed for# | Value of Placing Shares subscribed for# | Resulting shareholding following subscription # | Percentage of enlarged share capital following subscription# |
Stuart Gall | Chief Executive Officer | 828,236 | 95,238 | £10,000 | 923,474 | 0.34% |
Helen Jones | Chief Financial Officer | 0 | 95,238 | £10,000 | 95,238 | 0.04% |
Nicholas Sleep | Chief Technology Officer | 326,471 | 95,238 | £10,000 | 421,709 | 0.16% |
Ian Whittaker | Chief Operating Officer | 374,982 | 76,190 | £8,000 | 451,172 | 0.17% |
Nick Avis | Non-Executive Director | 225,000 | 47,619 | £5,000 | 272,619 | 0.10% |
#The number of Ordinary Shares presented in this table as being held or subscribed for by Directors refers to the number of Ordinary Shares held or subscribed for by them either personally or through a nominee.
Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as defined in the circular sent to shareholders of the Company on 17 April 2020.
The Company makes the following disclosures in accordance with article 19(3) of the Market Abuse Regulation:
1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
a)
| Name
| 1. Stuart Gall 2. Helen Jones 3. Nicholas Sleep 4. Ian Whittaker 5. Nick Avis | ||||
2 | Reason for the notification | |||||
a)
| Position/status
| 1. Chief Executive Officer 2. Chief Finance Officer 3. Chief Technology Officer 4. Chief Operating Officer 5. Non-Executive Director | ||||
b) | Initial notification /Amendment | Initial | ||||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Intelligent Ultrasound Group plc | ||||
b) | LEI | 213800K4ZVWL4ZYQAZ70 | ||||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a)
| Description of the financial instrument, type of instrument
Identification code | Ordinary Shares of 1 pence each
ISIN: GB00BN791Q39 | ||||
b) | Nature of the transaction | Purchase of Ordinary Shares | ||||
c)
| Price(s) and volume(s)
|
| ||||
d) | Aggregated information - Aggregated volume - Price |
N/A - single transaction | ||||
e) | Date of the transaction | 6 May 2020 | ||||
f) | Place of the transaction | London Stock Exchange, XLON | ||||
Enquiries:
Intelligent Ultrasound Group plc | www.intelligentultrasound.com |
Stuart Gall, CEOHelen Jones, CFO | Tel: +44 (0)29 2075 6534 |
Cenkos Securities plc | Tel: +44 (0)20 7397 8900 |
Giles Balleny (Nominated Adviser) | |
Michael Johnson/Julian Morse (Corporate Broking) | |
Walbrook PR | Tel: +44 (0)20 7933 8780 or intelligentultrasound@walbrookpr.com |
Anna Dunphy/Paul McManus | Mob: +44 (0)7876 741 001/Mob: +44 (0)7980 541 893 |
About Intelligent Ultrasound Group
Intelligent Ultrasound (AIM: MED) develops artificial intelligence-based clinical image analysis software tools for the diagnostic medical ultrasound market and hi-fidelity virtual reality simulators for the ultrasound training market.
Based in Cardiff and Oxford in the UK, Atlanta in the US and with representation in Beijing in Asia, the Group operates two divisions:
Clinical AI Division
Focusses on developing deep learning-based algorithms to make ultrasound machines smarter and more accessible. Products in development include ScanNav which uses machine-learning based algorithms to automatically identify and grade ultrasound images to provide scan assessment and audit of protocol-based ultrasound scanning; and AnatomyGuide, which aims to simplify ultrasound-guided needling by providing the user with real-time AI-based needle guidance software for a range of medical procedures.
Simulation Division
Focusses on hi-fidelity ultrasound education and training through simulation. Its three main products are the ScanTrainer OBGYN training simulator, the HeartWorks echocardiography training simulator and the BodyWorks Eve Point of Care and Emergency Medicine training simulator. To date over 800 simulators have been sold to almost 500 medical institutions around the world.
www.intelligentultrasound.com